




In this era of highly active antiretroviral
therapy (HAART), hepatitis B and C virus (HBV and HCV)
co-infection have emerged as significant co-morbid
conditions. Local reports indicate that co-infection is not
uncommon in Nigeria as in other sub-Saharan African
countries.Whether treatment outcomes of HIV mono-
infected patients differ from those with co-infection
remains largely unknown. We hypothesised that co-
infected patients will have lower CD4+ count recovery and
viral load reduction following HAART.
A cohort study in antiretroviral therapy-naïve
HIV-infected adults involving 150 cases (HIV and co-
infection) and 150 controls (HIV infection only). Patients'
care was according to the National guidelines and
patients received first line therapy mostly comprising
Lamivudine, Stavudine and Nevirapine. Medication
adherence was monitored using pharmacy computerised
system, and CD4+ cell counts and HIV viral load (VL)
were compared at baseline, 3 and 6 months of therapy.
There were 98(65.3%) and 96(64%) female
cases and controls (p=0.79) respectively.The mean ages
of cases and controls were 38±8.4 and 37±8.9 years
(p=0.20) respectively.Cases comprised 73(48%) HBV,
70(47%) HCV and 7(5%) with both HBV and HCV
infection.Medication adherence was >95% in both arms.
Attrition rate was 2.7%(8); seven of them were co-
infected. Five cases (3.3%) compared to zero controls
developed clinical hepatitis. The proportions of patients
with CD4+ count <200 cells/µl among cases and controls
were 111(74%) and 109(72%), p=0.36 at baseline;
66(45.5%) and 64(42.7%), p=0.21 at 3 months; 60(42%)
and 56(37.6%), p=0.40 at 6 months respectively.
Significantly, more controls (60.7%) had CD4+ increases
50cells/µl at 3 months compared to 37(54.5%) HCV+
cases (p=0.03). No significant difference in CD4+ counts
between controls and cases at 6 months. The baseline
median VL for cases and controls were log  4.95 and
log  4.83 (p=0.17) respectively. The proportions of cases
and controls with undetectable VL at 3 and 6 months were




A Prospective Cohort Study of Immunologic and Virologic Outcomes in Patients with
HIV/AIDS and Hepatitis Virus Co-Infection in Jos, Nigeria
*Isa S E **Gwamzhi L N , ***Akolo C , *Giyan JFWACP FWACP FWACP FWACP
Federal Medical Center, Keffi, Nigeria Grenada General Hospital, St Georges, St George's, Grenada, SRA




Conclusion: Co-infection has limited impact on
immunologic and virologic outcomes, but may be an
important cause of hepatotoxicity.
Key Words: HIV/AIDS, Hepatitis virus Co-Infection, HAART
Accepted as poster at 14th International Congress on Infectious
Diseases, Miami Florida USA
DateAccepted for Publication: 18 October 2009
NigerJMed 2010: 279 - 285
Copyright©2010 Nigerian Journal of Medicine
th
Introduction
Since the discovery of Acquired Immunodeficiency
Syndrome (AIDS) in 1981 and isolation of the Human
Immunodeficiency Virus (HIV) in 1984 , the disease has
become a pandemic. Currently, it is one of the most
important diseases worldwide. According to the
estimate from the Joint United Nations Programme on
HIV/AIDS, about 33.4 million people were living with
HIV/AIDS worldwide with an estimated 22.4 million in
Sub-Saharan Africa by the end of December, 2008 .
Sub-Saharan Africa is the home to 67% of the adults
living with HIV/AIDS in the world and registered up to
72% of about 2 million HIV/AIDS deaths in 2008. The
current global estimates put Nigeria as second in Sub-
Saharan Africa and fourth globally with an estimated 3
million people living with HIV/AIDS. Although South-
South Nigeria has the highest zonal averages, the
individual states with the highest HIV prevalence are
situated in the North Central zone.
As a result of shared routes of transmision , Hepatitis B
Virus or Hepatitis C Virus co infection with HIV is not
uncommon. Uneke et al reported HBsAg prevalence of
25.9% in those with HIV infection and 14.3% in those
without HIV infection among blood donors in Jos while
Idoko et al reported a prevalence of 10% for anti-HCV
and 9% for both anti-HCV and HBsAg respectively in
HIV infected patients in North Central Nigeria.
Highly Active Antiretroviral Therapy (HAART) has
become the standard treatment for patients with
HIV/AIDS worldwide . Effective HAART therapy leads to
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CD4+ T-lymphocytes which is associated with decreased
risk of opportunistic infections, hospitalization and
mortality . However, with the increasing life expectancy
of HIV infected persons treated with HAART, the
contributions of Hepatitis B and C infection as causes of
liver disease in the setting of immune dysregulation in
people living with HIV/AIDS is assuming greater
importance  .
On the other hand, hepatitis virus can induce excessive
immune activation which is increasingly being recognized
as an important pathogenic factor for HIV disease
progression. Although HBV has a marked hepatic
tropism, it has been shown that this virus is also able to
infect T-lymphocytes , suggesting that HIV and HBV
may encounter each other at the cellular level in co-
infected patients. The HBV genome encodes a 17-kDa
protein, termed HBxAg, which induces HIV-1
replication    . The HCV protein E2 may directly mediate
excessive immune activation as it lowers the threshold for
T cell activation following stimulation. HCV infection may
also interfere with the proximal points of the immune
cascade, such as dendritic cell functions which is key to
the evolution and regulation of immune responses to HIV
and HCV. The high incidence of auto-immune
phenomena such as cryoglobulinemia and vasculitis
occurring in hepatitis C also suggests immune
dysregulation brought about by excessive immune
activation.
An immune system already over-activated by HIV may not
be able to keep up with this additional drainage of its
reserves.
While it has been observed that the recovery of CD +cells
in response to HAART is blunted and progression to AIDS
is hastened in those who are co-infected with hepatitis B
or C compared with persons who are not , other studies
failed to show similar findings . The Swiss HIV Cohort
Study (SHCS) enrolled 3655 HIV-infected subjects
commencing HAART (37.2% of whom were also co-
infected with HCV) and the relative risk of an AIDS
defining illness or death was 1.7 in HCV positive persons
compared with HCV negative persons  . Importantly, this
effect was independent of HIV viral load during HAART,
active continuation of intravenous drug abuse (which may
be related to poor compliance with therapy), and the
number of changes to HAART during follow-up,
suggesting that compliance and hepato-toxicity issues did
not confound the result of this study.
A preliminary report on the Nigerian antiretroviral
programme indicated that between baseline and six
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copies/ml and the median CD4+ count was increased
by 140 cells/µl. The primary objectives of this study
were to determine the immunologic and virologic
responses to HAART in HIV patients co-infected with
HBV and/or HCV compared with controls at 3 and 6
months of therapy.
This is a prospective cohort study that was carried out at
the HIV out-patient clinic (clinic II) and medical wards of
the Jos university teaching hospital (JUTH), North
Central Nigeria to determine the immunologic and
virologic responses to HAART in patients infected only
with HIV (controls) compared with those co-infected
HBV and/or HCV (cases). Immunologic response was
assessed as increase in median CD4+ and proportion
of patients with CD4+ increases =50cells/µl while the
virologic response was assessed as log decrease in
median viral load and proportion of patients with
undetectable viral load from baseline after
commencement of HAART.
A sample size of 150 patients with HBsAg and/or HCV
anti-body was used for the study following approval by
the Research and Ethics Committee of JUTH. All the
patients signed an appropriate informed consent form
before enlisting in the study.
Patients included in the study satisfied the following
inclusion criteria; Positive test for HIV infection by
ELISA, Confirmation of HIV status by western blot,
Positive HBsAg and/or anti-HCV antibody as cases,
and eligible for Anti-retroviral therapy (ART) according
to 2005 Nigerian guideline
The exclusion criteria were; Patients already on Anti-
retroviral therapy, Patients less than 18 years of age and
decompensated liver disease.
One hundred and fifty consecutive cases and same
number of controls that satisfied the inclusion criteria
were recruited between November 2005 andApril 2006.
Each qualified patient had a comprehensive history
taken and detailed clinical examination performed. The
patients were followed up over a period of six months on
tablets of Lamivudine, Stavudine and Nevirapine; this
was the commonest first line HAART regimen. Patients
were counseled on adherence and drug pick-ups were
checked in the pharmacy computerized data-base.
Complicating diseases were recorded together with
therapeutic interventions. The same information was
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Hepatitis B surface antigen, Hepatitis C antibody, CD4+
count, HIV viral load, chemistry and haematology tests
were done for all patients in the study and control groups
at entry. The investigations were repeated at 3 monthly
intervals for analysis. CD4+ lymphocytes were counted
using Flow cytometry with CD4+ Easy Count kit-CY-R-
1004 while Viral Load was determined using Polymerase
Chain Reaction(PCR) technology with Amplicor HIV-1
Monitor® Test, Version 1.5. Lower limit of detection is
<400 copies/ml and all viral load results were log-
transformed. Other investigations were done when they
are indicated.
The Epi-Info Version 3.3 2004 statistical software was
used for statistical analysis. Results were presented as
tables, bar chart, median for skewed variables and means
± standard deviation. The student t-test was used for
comparison of means of paired variables while Chi-
square(X ) test was used to test proportions of categorical
variables. A p value of < 0.05 was considered significant
and values < 0.01, as highly significant in all statistical
comparisons.
A total of 300 patients were enrolled into the study, but
295(98.3%) and 292(97.3%) patients completed the third
month and sixth month of the study period respectively.
Seven cases compared to one control did not complete
the study. Among the cases, five patients discontinued
due to hepatotoxicity (two were concurrently on anti-
tuberculosis therapy) and two(28.6%) because of severe
muco-cutaneous reactions. One patient was lost to
follow-up among the controls.
The age and sex distribution of cases and controls are
shown in Figure 1. The mean (±SD) ages of the cases and
controls were 38.3±8.4 (22-66) years and 37.3±8.9 (21-
71) years respectively (p=0.20). There were 98(65.3%)
females and 52(34.7%) males among the cases while
































FIGURE 1 AGE AND SEX DISTRIBUTION OF CASES AND CONTROLS




























All patients in the case and control groups had HIV type
1 after testing for both HIV 1 and HIV 2. The cases had
73(48.0%) patients that were positive for HBsAg,
70(47.0%) for anti-HCV antibody and seven(5.0%) for
both HBsAg and anti-HCV.
Among the cases, a total of 381 doses of ARVs were
missed out of 26,100 doses estimated to be taken by
three months (145 patients x 60 doses/month x 3 =
26,100). This accounted for 1.5% of the total doses,
implying 98.5% adherence. The doses missed in the
control group by the same period was 351(1.3%) out of
a total of 27,000 estimated to be taken, implying
adherence of 98.7%. (p=0.70). Similarly, adherence by
the sixth month was 98.4% among the cases and 98.5%
among the controls (p=0.86).
The changes in median CD4+ count in the cases and
controls over the 6 month study period is shown in
Figure 2 while the proportion of patients among cases
and controls that achieved CD4+ count increase of 50 or
more cells/µl from baseline at 3 months and 6 months of
HAART is shown in Table 1.
Both cases and controls had median CD4+ count of
127cells/µl at baseline which rose to 208 cells/µl and
Immunologic Response to HAART
Figure 2. CHANGES IN MEDIAN CD4+ BETWEEN CASES AND CONTROLS
Figure 3.    THE CHANGES IN MEDIAN VIRAL LOAD IN CASES
AND CONTROLS
231 cells/µl at the third month of HAART respectively.
This corresponds to a median increase of CD4+ cells of
+81cells/µl for the cases and +104cells/µl for controls
(p=0.22). At the sixth month of HAART, median CD4+
count among the cases was 222 cells/µl and 250 cells/µl
among the controls. The median increase from baseline
to six months was therefore +95cells/µl for cases and
+123cells/µl for controls (p=0.26).
The proportion of patients with CD4+ count below the
critical value of 200 cell/µl at baseline among the cases
was 111(74%) and 109(72.7%) among the controls
(p=0.36). The proportion of those with CD4+ counts below
200cells/µl among cases was 66(45.5%) compared with
controls 64(42.7%) at 3 months of HAART (p=0.21), and
also among cases 60(42.0%) and controls 56(37.6%) at
the end of the study period (p=0.40).
However, when immunological response was measured
as an increase from baseline of at least 50cells/µl, the
proportion of patients with CD4+ count increase =
50cells/µl at the third month of HAART were 88(60.7%)
for cases and 99(66%) for controls (p=0.01). At the end of
the study period, 95(67.4%) cases and 101(67.8%)
controls had increase of =50cells/µl (p=0.74).
Furthermore, when the cases that achieved CD4+
increase of =50cells/µl at 3 months of HAART were sub-
analyzed as those with HBsAg or anti-HCV and
compared with controls, HBsAg positive cases were
48(68.6%); p=0.53 while anti-HCV positive patients were
37(54.5%); p=0.03. There was statistically significant
difference in CD4+ increase of =50cells/µl between
controls and anti-HCV positive, but not HBsAg positive
patients. On the other hand, there was no statistically
significant difference in CD4+ increase of =50cells/µl at 6
months of HAART between HBsAg positive patients
48(64.7%); p=0.14 and anti-HCV positive patients
44(64.7%); p=0.14 when compared with controls.
The comparison of median CD4+ cells of cases and
controls with TB to their counterparts without TB at
baseline, at 3 months and at 6 months did not show
statistically significant difference in median CD4+ counts.
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Table I. Immunologic response in cases and controls at third and sixth month of haart
CD4 INCREASE 3 MONTHS 6MONTHS
CASES      CONTROLS CASE CONTROLS
N (%)           N (%) N (%) N (%)
PRESENT 88(60.7) 99(66) 96(67.1) 101(67.8)
ABSENT 57(39.3) 51(34) 47(32.9) 48(32.2)
TOTAL 145(100) 150(100) 143(100) 149(100)
X2 = 6.05 DF= 1 P=0.01 X2=0.11 DF=1 P=0.74
Virologic Response
The median viral load for the cases and controls are
shown in Table II while the proportion of patients with
undetectable viral load at 3 months and 6 months of
HAART is shown in Table III. The trends in viral load
from the beginning to the end of the study is shown in
figure 3.
At baseline, the median viral load in for cases and
controls were log 4.95, log  (IQR 4.01-6.45) and log
4.83, log  (IQR 3.87-6.37) respectively (p=0.17). By the
third month of HAART, the median viral load had
become less than log  2.60 (undetectable), log  (IQR
2.60-6.04) and less than log  2.60, log  (IQR 2.60-6.27)
for cases and controls respectively (p=0.86). Similarly,
at the end of the study period, median viral load was less
than log 2.60, log  (IQR 2.60-5.47) and less than
log  2.60, log  (IQR 2.60-5.14) for cases and controls
respectively (p=0.25). In absolute numbers, the median
viral load of 90,109 copies/ml for cases and 67,522
copies/ml for controls reduced to less than 400
copies/ml at three and six months of HAART. Hence, a
median viral load reduction of at least log  2.35 was
recorded for the cases and log  2.23 for controls at the
third and sixth month of HAART. The median viral load
was log  5.02 in HBsAg positive patients (p=0.38) and
log  4.83 in anti-HCV positive patients (p=0.56) when
compared to controls at baseline. The median viral load
was log  2.60 in HBsAg and anti-HCV positive patients
at 3 months when compared with controls (p=0.58), and
log  2.60 in HBsAg and anti-HCV at 6 months when
compared with controls (p=0.48).
There were 96(66.2%) and 97(65.5%) patients with
undetectable viral load by the third month of HAART
among the cases and controls respectively (p=0.74).
The number of patients with undetectable viral load
increased to 116(81.1%) and 119(79.3%) among the
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Table II. Changes in median viral loads of cases and controls
Discussion
The immunologic and virologic responses in this study
demonstrate that effective antiretroviral therapy can have
profound improvements in outcomes for those with HIV
co-infection with HBV or HCV similar to those with HIV
mono-infection.
In this study, immunologic response was significantly
lower among the cases 88(60.7%) when compared with
controls 99(66%) at the third month of HAART. When
cases were separated into HBsAg and anti-HCV positive
patients, the statistical difference was found only in the
anti-HCV positive cases as just 54.5% of them achieved
CD4+ increase of =50cells/µl from baseline at 3 months
compared to 66% of controls. Greub et al defined an
immunologic response to treatment as an increase in the
CD4+ cell count of at least 50 cells/µl from baseline and
found that HCV co-infection was associated with a smaller
CD4+ cell recovery in the Swiss Cohort Study. Zala et al
also reported that while 86% of HCV negative individuals
had a CD4+ cell count increase of =75cells/µl at 48
weeks, only 64% of HCV positive individuals achieved
this. Similarly, Klein et al reported that co-infected
individuals had a significantly reduced probability of





found no statistically significant difference in mean
CD4+ cell count 24 months after initiation of HAART with
adjustment for baseline CD4+ cell count, viral load,
previous nucleoside drug experience and duration of
HIV infection. Law et al found that the mean increases
in CD4+ count of 100 cells/µl were significantly lower
among HIV patients co-infected with HBV and HCV at
weeks 4 and 8 following commencement of HAART,
however by week 48 CD4+ cell increases were similar.
In contrast to the significant association between
infection with HCV infection and reduced immunologic
response at 3 months in this study, Sulkowski et al in a
United States-based study of 1995 patients reported no
difference in CD4+ count rise and disease progression
in those co-infected with HCV compared to HIV mono-
infected patients. The disparity in findings may be
related to the fact that 72% of his patients were not
receiving HAART, 25% progressed to AIDS and 16%
died. Therefore, the high mortality in their study may
have prevented the observation of late and subtle
changes in CD4+ counts.
The lack of consistency in results in several of the
studies may stem from different definitions for what
constitutes immunologic response, inconsistencies in
the unit of measures and the fact that it can take 24
months of treatment for complete immunologic
response to occur  , beyond the time frame of many
studies including this study. Also, confounders like
intercurrent infection, psychological stress e.t.c
responsible for decreases in CD4+ were not assessed.
Furthermore, blunted response may mostly occur in
those co-infected individuals with lower baseline CD4+
counts as is usually seen in Africa. For example, in
Klien's study where no difference in mean CD4+ cell
count response was observed, the baseline CD4+ cell
count was well above 200 cells/µl among co-infected
and HIV mono-infected individuals. Lamivudine which is
active against both HIV and HBV may blunt the full effect
of HBV as reported in the CAESAR study even though
Law et al reported no differential CD4+ cell response in
HIV-HBV co-infected patients with and without
lamivudine-containing antiretroviral therapy regimens.
Lastly, positive HBsAg and anti-HCV serology do not
translate to active infection and may justify similar
treatment outcomes between cases and controls.
The baseline median viral load was higher among the
cases (log  4.95) compared with controls (log  4.83)
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DURATION
(months) 0 3 6
STUDY GROUP
Cases controls Cases controls Cases controls
MEDIAN VIRAL LOAD
Log10
4.95 4.83 <2.60 <2.60 <2.60 <2.60
RANGE
Log10 4.01-6.45 3.87-6.37 2.60-6.04 2.60-6.27 2.60-5.47 2.60-5.14
p-value =0.17 =0.86 =0.25
Table III. Proportion of patients with undetectable viral load at third and sixth month of haart
VIRAL LOAD 3 MONTHS 6 MONTHS
GROUP CASES CONTROLS CASES         CONTROLS
N (%)                         N (%) N (%) N (%)
UNDETECTABLE 96(66.2) 97(64.7) 116(81.1) 119(79.3)
DETECTABLE 49(33.8) 53(35.3) 27 (18.9) 30(20.7)
TOTAL 145(100) 150(100) 143(100) 149(100)
X2 = 0.11 DF= 1 P=0.74 X2= 2.67 DF=1 P=0.10
log  2.3 for cases and log 2.2 for controls at 3 and 6
months of HAART (p=0.86 at 3 months, p=0.25 at 6
months). Similar to this study, some reports from
developing and developed countries on the efficacy of
various antiretroviral regimens have documented
reductions in viral load levels between log  1.5 to log  2.0
within 6 months . These findings also agree with those
of Grueb et al, and Law et al where median viral load
reduction was log  1.5 in patients with and without co-
infection from week 4 up to 48 following initiation of
HAART.
Although statistically non-significant, the higher baseline
viral load among the cases (especially HBsAg positive)
than controls may be attributed to the ability of HBV
protein X to stimulate HIV viral replication as reported in







significant difference between the proportion of patients
with undetectable viral load among the cases (66.2%)
and controls (64.7%) at 3 months. Similarly, there was
no significant difference in proportion of patients with
undetectable viral load among cases (81.1%) and
controls (79.3%) at the end of the study period.
HIV infection in the presence of positive HBsAg or anti-
HCV has limited impact from the point of view of
immunologic and virologic outcomes. This may indicate
that the commonly available and cheap ARVs will be in
use until better and affordable alternatives are
available. Regardless, a management plan is
advocated to prevent co-infection and ameliorate other
challenges it presents in HIV/AIDS patients.
Conclusion
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